Medical aspects of pelvic inflammatory diseases
https://doi.org/10.21518/2079-701X-2018-7-40-44
Abstract
Inflammatory pelvic diseases (IPD) are associated with increased incidence of sexually transmitted infections. The modern features of the PID course raise the question of including drugs improving therapy outcomes in the combination PID therapy. The development of chronic inflammatory processes is accompanied by changes in the body’s immune system, which serves as a basis for developing and finding new therapeutic agents and methods that have an effective therapeutic effect aimed at restoring the function of the impaired human immune status as a whole. The synthetic low molecular weight immunomodulating drug with anti-inflammatory activity aminodihydrophthalazinedione sodium possesses the above described therapeutic potential.
About the Authors
E. R. Dovletkhanova
V.I. Kulakov National Medical Research Centre for Obstetrics, Gynaecology and Perinatology of the Ministry of Health of RF
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
P. R. Gatsura
V.I. Kulakov National Medical Research Centre for Obstetrics, Gynaecology and Perinatology of the Ministry of Health of RF
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
A. N. Mgeryan
V.I. Kulakov National Medical Research Centre for Obstetrics, Gynaecology and Perinatology of the Ministry of Health of RF
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
References
1. Sexually Transmitted Diseases Treatment Guidelines, СDC. MMWR. June 5, 2015, 64(3). 137 с.
2. Kubanova AA, et al. Analysis of the epidemiological situation and the dynamics of the incidence of sexually transmitted infections and dermatoses on the territory of the Russian Federation. Vestnik Dermatologii i Venerologii, 2010, 5.
3. Low N, Broutet N, Adu-Sarkodie Y, Barton P, Hossain M, Hawkes S. Global control of sexually transmitted infections. Lancet, 2006 Dec 2, 368(9551): 2001-2016.
4. Wiesenfeld HC, Sweet RL, Ness RB, et al. Comparison of acute and subclinical pelvic inflammatory disease. Sex Transm Dis, 2005, 32: 400-405.
5. Patton DL, Wolner-Hanssen P, Zeng W, Lampe M, Wong K, Stamm WE et al. The role of spermatozoa in the pathogenesis of Chlamydia trachomatis salpingitis in a primate model. Sex Transm Dis, 1993 Jul-Aug, 20(4).
6. World Health Organization. Sexually transmitted infections. Available athttp://www.who.int/ mediacentre/factsheets/fs110/en/. Accessed February 2, 2010.
7. Electronic resource of FGBU Central Research Institute of Healthcare Management and Informatization of the Ministry of Health of the Russian Federation. The general morbidity of the adult population of Russia in 2014. http://www.mednet.ru/index.php?option=com_user&view=login&return=aHR0cDovL3d3dy5tZWRuZXQucnUvc3RhdGlzdGlrYS5odG1sP2xhbmc9cnU= дата обращения: 04.06.2016.
8. RF Federal State Statistics Service http://www.gks.ru/wps/wcm/connect/rosstat_main/rosstat/ru/statistics/population/demography/# Accessed date: 14.06.2016.
9. Gomberg MA. Reproductive health and infections caused by C. trachomatis. Ginekologiya, 2011, 1: 13-16.
10. Sexually Transmitted Diseases Treatment Guidelines, 2010. MMWR, 2010, 59(RR-12).
11. Lanjouw E, Ossewaarde JM, Stary A, Boag F. Редактор: WI van der Meijden, European guidelines for the diagnosis and treatment of infections caused by Chlamydia trachomatis. Date of review: July 2010.
12. Bevan CD et al. Efficacy and safety of azithromycin as monotherapy or combined with met-ronidazole compared with two standard multid-rug regimens for the treatment of acute pelvic inflammatory disease. Journal of International Medical Research, 2003, 31(1): 45-54.
13. Mikamo H et al. Efficacy and safety of intravenous azithromycin followed by oral azithromycin for the treatment of acute pelvic inflammatory disease and perihepatitis in Japanese women. J Infect Chemother, 2014, 20: 429-435.
14. Kintner J, Lajoie D, Hall J, Whittimore J, Schoborg R. Commonly prescribed β-lactam antibiotics induce C. trachomatis persistence/ stress in culture at physiologically relevant concentrations. Frontiers in Cellular and Infection Microbiology, 2014, 4(44): 1-10.
15. Grayston JT et al. Azithromycin for the secondary prevention of coronary events. N Engl J Med, 2005; 352: 1637-1645.
16. Letyaeva OI, Gizinger OA. Immunomodulating therapy as a correction method of immunomicrobiological urogenital tract disorders in chlamydial infection complicated by bacterial vaginosis. Gynekologiya, 2011, 1: 16-21.
17. Medyannikova IV, Kravchenko EN. Immunocorrective therapy of female lower urinary tract diseases. Akusherstvo i Ginekologiya, 2010, 5: 107-110.
18. Markos AR. The concordance of Chlamydia trachomatis genital infection between sexual partners, in the era of nucleic acid testing. Sex Health, 2005, 2: 23-24.
Review
For citations:
Dovletkhanova ER, Gatsura PR, Mgeryan AN. Medical aspects of pelvic inflammatory diseases. Meditsinskiy sovet = Medical Council. 2018;(7):40-44. (In Russ.) https://doi.org/10.21518/2079-701X-2018-7-40-44
Views:
602
Email this article 